Medicare GLP-1 Coverage: Everything Changing in July 2026

Update July 3, 2026: The Medicare GLP-1 Bridge Demonstration is now live. Medicare now covers Wegovy, Zepbound, and Foundayo for weight loss at a flat $50/month copay — the program launched July 1, 2026 as scheduled. Approximately 3.4 million Medicare beneficiaries qualify. The Medicare GLP-1 Bridge Demonstration, announced by CMS on December 23, 2025, marks the first time Medicare has covered weight loss drugs since Part D began in 2006. The prior authorization form and eligibility criteria are available — your provider can submit a prior auth now. Use our insurance coverage lookup to check your specific plan, or compare all 49 providers to find one that accepts Medicare.

What Does the Medicare GLP-1 Bridge Program Cover?

• •Launch date: July 1, 2026 (program runs through December 31, 2027)
• •Your cost: $50/month copayment, does NOT count toward the $2,100 annual Part D out-of-pocket cap
• •Medications covered: Wegovy (semaglutide injection + oral tablets), Zepbound (tirzepatide KwikPen), and Foundayo (orforglipron)
• •Negotiated manufacturer price: $245/month (paid by the program)
• •Who qualifies: Medicare Part D enrollees meeting the three-tier BMI criteria (see below), NOT patients already covered for T2D, OSA, MASH, or established CVD
• •Estimated eligible population: ~3.4 million Medicare beneficiaries

This is a significant shift. Until now, Medicare Part D explicitly excluded weight loss drugs. Coverage was only available for GLP-1s prescribed for Type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea, not weight management alone.

How Does Medicare GLP-1 Pricing Work?

The pricing structure came from a Most-Favored-Nation deal between the Trump administration and both Novo Nordisk and Eli Lilly. Both manufacturers agreed to a net price of $245/month, roughly 75-80% below the retail list price.

For context, Wegovy lists at approximately $1,349/month and Zepbound at about $1,086/month. The $245 negotiated price represents the lowest official price point for brand-name GLP-1s anywhere in the US system.

Additionally, the Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap (effective since 2025) provides a backstop, even if you use other medications, your total annual prescription spending is capped.

Who Qualifies for Medicare GLP-1 Coverage?

The Bridge is for Medicare Part D beneficiaries who want GLP-1 treatment solely for weight management. CMS released the prior authorization form and uses a three-tier BMI system. You must meet one of the following tiers at the time you initiated GLP-1 therapy (not necessarily today, see BMI timing note below):

• •Tier 1, BMI ≥ 35: No additional diagnosis required.
• •Tier 2, BMI ≥ 30 with at least one of: heart failure with preserved ejection fraction (HFpEF); uncontrolled hypertension (systolic >140 mmHg or diastolic >90 mmHg despite two antihypertensive medications); OR chronic kidney disease stage 3a or higher.
• •Tier 3, BMI ≥ 27 with at least one of: pre-diabetes (per ADA guidelines); prior myocardial infarction; prior stroke; OR symptomatic peripheral artery disease.

BMI timing rule: Eligibility is assessed at the time you *initiated* GLP-1 therapy, not the day you submit the PA form. If you started a GLP-1 in 2024 with a BMI of 37 and your BMI is now 33, your prescriber attests to your initiation BMI. This also applies to patients who started GLP-1 therapy before enrolling in Medicare Part D.

Prior Authorization: How the Process Works

CMS has released the Prior Authorization Request Form and the Information for Prescribers sheet. Prior authorization requests will not be accepted or processed before July 1, 2026, there is no pre-filing queue. Here's how the process works:

• •Who submits: Your prescribing provider submits the PA, not you. Providers should download the Prescriber Information sheet first.
• •How to submit: Electronically via CoverMyMeds (covermymeds.com), strongly preferred, or by fax using the PDF form at cms.gov/glp-1-bridge.pdf. Do not send to CMS directly or to your Part D plan.
• •Who processes it: Humana, acting as CMS's central processor (using LI NET infrastructure), separate from your Part D plan. Claims route through BIN 028918 / PCN MEDDGLP1BR, not your normal Part D benefit.
• •What the form asks: Your provider attests to your BMI tier at therapy initiation, confirms you don't have a T2D/OSA/MASH/CVD indication that routes to regular Part D, and selects the drug requested (Wegovy, Zepbound, or Foundayo).

What Comes After: The BALANCE Model (Part D Delayed Indefinitely)

The Bridge program was originally designed as a temporary on-ramp to the larger BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth). However, CMS announced on April 21, 2026 that the Part D portion of the BALANCE Model is delayed indefinitely, cited reason: insurers wanted more utilization data before committing. The Bridge was simultaneously extended through December 31, 2027 to fill the gap. Source: AHA News, April 22, 2026

• •Part D portion of BALANCE: Delayed indefinitely as of April 2026, no confirmed start date
• •State Medicaid agencies: Can opt in starting May 2026 (Medicaid BALANCE portion was not delayed)
• •The Bridge: Extended through December 31, 2027 specifically because the Part D BALANCE launch was pushed back
• •What this means for patients: Your Bridge coverage runs through December 31, 2027, after that, there is no confirmed follow-on program for Medicare Part D yet

Is the $50 Bridge actually your cheapest path?

Here's the part CMS won't tell you: most Medicare beneficiaries won't clear the Bridge's BMI-and-condition tiers, and even if you do, $50/month for a brand-name drug isn't automatically the cheapest route once you account for the prior authorization and qualifying-condition hoops. Based on our price audit of GLP-1 providers, here's how the $50 Bridge actually compares to the cash-pay market you can access without Medicare:

• •$50/month, Medicare Bridge (brand Wegovy, Zepbound, or Foundayo): the cheapest brand-name option anywhere, *if* you qualify (BMI tier + active Part D + provider-submitted prior auth), and only from July 1, 2026 through December 31, 2027.
• •$99–$149/month, cash-pay compounded semaglutide or tirzepatide: no Medicare, no qualification tiers, no prior authorization, available today. See the current floor on our cheapest GLP-1 page.
• •$149/month, cash-pay oral Foundayo: the same orforglipron pill the Bridge covers, with no eligibility gate.
• •After December 31, 2027, uncertain: The BALANCE Model Part D launch was delayed indefinitely. After the Bridge ends, there is no confirmed Medicare GLP-1 coverage pathway yet. Watch CMS announcements for 2028 planning.

Run your own numbers with our cost calculator, or compare the cheapest verified cash-pay programs side by side on our cheapest GLP-1 providers page before you assume the Bridge is your lowest-cost path.

What to Do Now

July 1 is days away. Here's the preparation checklist:

• •Check your eligibility path first: Do you have T2D, OSA, MASH, or established CVD? If yes, ask your prescriber about coverage through your regular Part D plan, that's a separate process from the Bridge.
• •Confirm your initiation BMI is documented: The PA form asks for BMI at the time you started GLP-1 therapy. Ask your doctor to confirm this is in your chart, especially if you started treatment more than a year ago.
• •Share the prescriber info with your doctor: Send them the CMS Prescriber Information sheet and the PA form now so they're ready to submit on July 1.
• •Ensure your Medicare Part D plan is active: The Bridge requires active Part D enrollment; confirm with your insurer.
• •Starting July 1: Your provider submits the PA via CoverMyMeds; pharmacy fills using Bridge BIN/PCN (not your normal Part D); your copay is $50.
• •After December 2027: The Bridge program ends December 31, 2027. The BALANCE Model Part D launch has been delayed indefinitely, there is no confirmed follow-on pathway yet. Monitor CMS updates starting mid-2027 for what comes next.